Europe’s first commercial facility for psychedelic drug trials is to open in London, with the goal of making the UK a global leader in psychedelics research and innovation.
The British startup Clerkenwell Health aims to begin trials in its central London facility in August, initially focusing on the use of psilocybin to help people deal with the anxiety associated with a diagnosis of terminal illness, and to support them through their end-of-life care.
